Paul Reichert, MS

Kenilworth, New Jersey, United States
Paul Reichert is an Associate Principal Scientist in the Structural Chemistry Department at Merck Research Laboratories (MRL). He has been conducting pharmaceutical research for 35 years working at MRL on the discovery and development of small molecule and macromolecular therapeutics. His expertise is primarily in the crystallization of proteins and biologics to better patient treatment options for efficacy, safety, adherence, and compliance.
Paul has over 25 pharmaceutical application patents of crystalline proteins and is also the author of over 31 papers on the development of biologic therapeutics. He established a high throughput (HT) crystallization lab to research and develops HT macromolecular crystallization strategies and screening methodologies. As an integral member of a multidisciplinary team, he developed novel, controlled release biological health care technologies and brought them to market.
Most noteworthy, he was a member of a team which developed the manufacturing process for alpha interferon product; Intron A™ and PEG Intron A™. The alpha-2 interferon products, for example, fulfilled an unmet medical need for hepatitis C and melanoma patients.
For 15 years, in collaboration with NASA and the University of Alabama at Birmingham, he has had both advisory and scientific roles. He was a member of the Science Advisory Group for NASA's Iterative Biological Crystallization Group at Marshall Space Flight Center. He has been a principal investigator for eleven microgravity experiments on Space Shuttle flights as secondary payloads. These experiments were designed to explore microgravity effects on multiple pharmaceutical applications primarily using alpha interferon (Intron A™). These patient-centric applications included structure determination, drug delivery and the purification of protein therapeutics with implications for health economics and outcomes.
Currently, besides his work at MRL, Paul is a principal investigator in collaboration with CASIS and has performed experiments for crystallization of therapeutic monoclonal antibodies on Space X-CRS-3, 6, 10 and 24 missions to the International Space Station (ISS). The results of the SpaceX-CRS-10 experiment were published in Nature; Reichert, P., Prosise, W., Fischmann, T.O. et al. Pembrolizumab microgravity crystallization experimentation. npj Microgravity 5, 28 (2019). He was also appointed to the International Space Station National Lab (ISS-NL) User Advisory Committee (UAC) Science Subcommittee (July 2021). Most recently, his monoclonal antibody crystallization experiment launched on board SpaceX-CRS-24 December 21st 2021and was recovered on January 24, 2022. Biophysical and biochemical characterization studies are ongoing.
Speaking In
10:45 AM - 12:00 PM (PDT)
Tuesday, June 14
A new era in space-based scientific investigation started with the first all-private astronaut…